Screening for colorectal cancer saves money by avoiding the need for costly new chemotherapy drugsBMJ 2009; 339 doi: http://dx.doi.org/10.1136/bmj.b3934 (Published 25 September 2009) Cite this as: BMJ 2009;339:b3934
- Susan Mayor
Most colorectal cancer screening strategies would save healthcare systems money by picking up cases at an earlier stage and preventing the need for costly chemotherapeutic drugs, which have recently become available, a study has found.
The United States used a microsimulation model to assess whether the increasing use of new, costly drugs would affect the treatment savings that could be achieved by colorectal cancer screening (J Natl Cancer Inst 2009 doi:10.1093/jnci/djp319). The MISCAN-Colon model—the colorectal version of a model previously used to evaluate screening programmes for breast, cervical, and prostate cancer—simulates …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial